Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure

Michael Godschalk, David Gheorghiu, Juza Chen, P. Gary Katz, Thomas Mulligan

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We determined the long-term efficacy of intracavernous injection of a new formulation of prostaglandin E1 (Caverject) as treatment for erectile failure. Materials and Methods: A prospective study was done at a university affiliated Veterans Affairs medical center. Subjects with erectile failure received injections of prostaglandin E1 at the office and self- administered injections at home for up to 18 months. Results: Of 16 patients who performed home injections 15 completed 6 months and 10 completed 18 months of therapy. Patient and spousal satisfaction with intercourse was 90% for months 1 to 6, and patient satisfaction was 95% for months 7 to 18. Conclusions: Prostaglandin E1 was highly effective at producing penile rigidity and an erection with satisfactory vaginal intercourse.

Original languageEnglish
Pages (from-to)915-917
Number of pages3
JournalJournal of Urology
Volume155
Issue number3
DOIs
StatePublished - Mar 1996
Externally publishedYes

Keywords

  • drug therapy
  • impotence
  • penile erection
  • penis
  • prostaglandins E

Fingerprint

Dive into the research topics of 'Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure'. Together they form a unique fingerprint.

Cite this